Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Trial of LY2940680 in Pediatric Patients With Recurrent or Refractory Rhabdomyosarcoma or Medulloblastoma

NCT01697514 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT01697514
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01697514 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Trial of LY2940680 in Pediatric Patients With Recurrent or Refractory Rhabdomyosarcoma or Medulloblastoma
Lead sponsor
Eli Lilly and Company
Phase
Phase 1
Overall status
Withdrawn
Start date
July 31, 2013
Completion date
July 31, 2016
Enrollment
0 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

medulloblastoma, childhood, rhabdomyosarcoma